---
title: "Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296602035.md"
description: "Needham analyst Gil Blum initiated a Buy rating on Faeth Therapeutics (FTH) with a $56 price target, citing its oral multi-node PI3K/AKT/mTOR strategy. The Piktor regimen shows encouraging activity in endometrial cancer, positioning it as an attractive fast follower. H.C. Wainwright also reiterated a Buy rating with a $60 target."
datetime: "2026-08-21T09:55:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296602035.md)
  - [en](https://longbridge.com/en/news/296602035.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296602035.md)
generator: "portal-rs"
---

# Faeth Therapeutics Initiated at Buy on Oral Multi‑Node PI3K/AKT/mTOR Strategy; Analyst Sets $56 Price Target

Gil Blum, an analyst from Needham, has initiated a new Buy rating on Faeth Therapeutics (FTH).

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Gil Blum has given his Buy rating due to a combination of factors, centered on Faeth Therapeutics’ strategy of targeting the PI3K/AKT/mTOR pathway with an oral, multi‑node approach. He notes that a recently approved, clinically validated multi‑node inhibitor in this pathway has established proof of concept, but its IV dosing and positioning may constrain use in earlier treatment settings.

Blum highlights that Faeth’s Piktor regimen combines an oral PI3Kα inhibitor with an oral mTORC1/2 inhibitor, showing encouraging initial activity in endometrial cancer and aligning with the oncology shift toward oral standards of care. He believes this profile positions Piktor as an attractive fast follower opportunity, supporting his Buy rating on FTH and a $56 price target. 

Blum covers the Healthcare sector, focusing on stocks such as Nurix Therapeutics, Fate Therapeutics, and Cartesian Therapeutics. According to TipRanks, Blum has an average return of 16.6% and a 46.77% success rate on recommended stocks. 

In another report released on August 11, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.

### Related Stocks

- [FTH.US](https://longbridge.com/en/quote/FTH.US.md)
- [NRIX.US](https://longbridge.com/en/quote/NRIX.US.md)
- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)
- [RNAC.US](https://longbridge.com/en/quote/RNAC.US.md)

## Related News & Research

- [AC Immune reports positive interim Phase 1 data for NLRP3 inhibitor ACI-19764](https://longbridge.com/en/news/296478492.md)
- [Roth MKM Sticks to Its Buy Rating for Coya Therapeutics, Inc. (COYA)](https://longbridge.com/en/news/296711581.md)
- [Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004](https://longbridge.com/en/news/296680419.md)
- [Alliance Global Partners Reaffirms Their Buy Rating on Pelthos Therapeutics (PTHS)](https://longbridge.com/en/news/296781912.md)
- [Eikon CEO Perlmutter joins Cantor Fitzgerald KOL webcast on PARP inhibitors in oncology](https://longbridge.com/en/news/296265619.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**